News

/News

Intensity Therapeutics reports tumor regression

Intensity Therapeutics of Wesport says that its lead drug INT230-6 6 results in complete response of tumors in rodent models, induces protective T-cell immunity and is synergistic with checkpoint inhibitors. Intensity’s Chief Executive Officer Lewis H. Bender said, “The direct killing action and immune response data generated in rodent models from our lead drug INT230-6 are impressive. We hope these animal results translate into an equally potent response in our clinical study.” more

By |April 9th, 2017|News|0 Comments

Yale: Testing a new drug for sudden deafness

Sudden hearing loss, which physicians call sudden sensorineural hearing loss, or SSHL, is an unexplained, rapid loss of hearing — usually in one ear. About half of the people who experience it will regain most or all of their hearing spontaneously, but the other half will not. Elias Michaelides, MD, an ear, nose, and throat physician at Yale Medicine, wants to improve those odds through a clinical trial to test a new drug for this condition. more

By |April 9th, 2017|News|0 Comments

Alexion appoints Ludwig Hantson CEO

Alexion Pharmaceuticals has announced the appointment of Ludwig N. Hantson, Ph.D., as Chief Executive Officer and member of the Board of Directors, effective immediately. Dr. Hantson most recently served as President and CEO of Baxalta, a successful spin-off as a public company from Baxter, and a global leader in the development of therapies for orphan and underserved diseases in hematology, immunology and oncology. He succeeds David R. Brennan, who has led the company as Interim CEO since December 2016. Mr. Brennan will remain on the Board of Directors and the Board expects to appoint him Chairman. more

By |April 9th, 2017|News|0 Comments

Bipartisan call to empower Connecticut bioscience

With precision medicine becoming big business in Connecticut, the Commerce Committee has produced bipartisan proposals to coordinate efforts across the state, prepare Connecticut’s workforce and position Connecticut as a national leader in biomedical research. Members of the committee have stressed the need for cooperative support from government, education and private business in growing Connecticut’s bioscience sector. more

By |April 9th, 2017|News|0 Comments

Protein Sciences gears up for China outbreak

In  light of the growing concern over recent Avian Influenza outbreaks in China, Protein Sciences Corporation, maker of the highly effective Flublok® Influenza Vaccine, reports that the Biomedical Advanced Research and Development Authority (BARDA) has requested the development of two new pandemic vaccine candidates to combat new H7N9 strains, one representing a pathogenic H7N9 virus. more

By |April 9th, 2017|News|0 Comments

CURE welcomes Assembly Biosciences, Inc.

Assembly Biosciences, Inc. is a biotechnology company advancing two innovative platform programs: (i) HBV-cure program, which is advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and (ii) microbiome program, which is a novel class of oral biological therapeutics, which are designed to restore health to a dysbiotic microbiome ... more​ Assembly Biosciences is currently hiring, with the following positions open in Groton, CT: * Senior Scientist/Senior Manager – Analytical Development * Associate Scientist/Senior Associate Scientist/Scientist – Analytical Development * Associate Scientist/Scientist, Drug Product Development * Scientist/Sr. Scientist, Preformulation-Formulation Development * Research Scientist/Associate [...]

By |April 9th, 2017|News|0 Comments

P2 Science to build manufacturing plant in New Haven

Elm Street Ventures announced today that P2 Science, Inc., the portfolio company it co-founded with Yale University, has closed on a $9.6 million Series B financing round. The new equity will enable P2 Science to build its first commercial production plant in the New Haven area, close to its headquarters in Woodbridge, CT. P2 Science is a specialty chemicals company with a unique flow chemistry process that converts renewable feedstocks into high-value products and intermediates, with an initial focus on the flavors and fragrances industries.​ “The potential for P2’s technology is enormous, and we are delighted that the company’s first [...]

By |April 9th, 2017|News|0 Comments

Jackson Lab hiring in Connecticut in 2017

The drive to advance precision medicine at The Jackson Laboratory for Genomic Medicine (JAX) in Farmington, Conn., began in 2014. To continue the momentum, JAX is now seeking to hire over 60 genomic researchers, bioinformaticians, software/IT engineers and administrative staff to join JAX’s world-class faculty and staff in their quest to find precise genomic solutions for disease. On March 28, from 4 p.m. to 7 p.m., JAX has set a Career Forum open house for scientists and professionals interested in opportunities at JAX. Candidates unable to attend the event are still encouraged to learn about JAX opportunities and to apply [...]

By |April 9th, 2017|News|0 Comments

FDA accepts extended use filing re Alexion’s Soliris®

The FDA has accepted for review Alexion’s supplemental Biologics License Application to extend the indication for Soliris® (eculizumab) as a potential treatment for patients with refractory generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive​ ... more Separately, Alexion has submitted an application to Japan’s Ministry of Labour and Welfare to similarly extend the indication for Soliris® ... more

By |April 9th, 2017|News|0 Comments

Achillion wins patent re complement factor D

The U.S. Patent and Trademark Office has issued the first U.S. Patent to Achillion resulting from its complement factor D research program.​ "Achillion's aim is to establish a broad patent portfolio for its complement program. With the granting of this first patent we are pleased that the USPTO has confirmed that Achillion possesses a multitude of patentable complement factor D inhibitors," commented Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion. "As a leader in AP (alternative pathway) biology, we are proud to have been the first to clinically demonstrate, in healthy volunteers, the ability to suppress AP activity [...]

By |April 9th, 2017|News|0 Comments